1. Home
  2. CCCC vs UTMD Comparison

CCCC vs UTMD Comparison

Compare CCCC & UTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCCC
  • UTMD
  • Stock Information
  • Founded
  • CCCC 2015
  • UTMD 1978
  • Country
  • CCCC United States
  • UTMD United States
  • Employees
  • CCCC N/A
  • UTMD N/A
  • Industry
  • CCCC Biotechnology: Pharmaceutical Preparations
  • UTMD Medical/Dental Instruments
  • Sector
  • CCCC Health Care
  • UTMD Health Care
  • Exchange
  • CCCC Nasdaq
  • UTMD Nasdaq
  • Market Cap
  • CCCC 175.1M
  • UTMD 185.2M
  • IPO Year
  • CCCC 2020
  • UTMD N/A
  • Fundamental
  • Price
  • CCCC $2.23
  • UTMD $62.72
  • Analyst Decision
  • CCCC Strong Buy
  • UTMD
  • Analyst Count
  • CCCC 4
  • UTMD 0
  • Target Price
  • CCCC $8.50
  • UTMD N/A
  • AVG Volume (30 Days)
  • CCCC 1.8M
  • UTMD 7.9K
  • Earning Date
  • CCCC 10-30-2025
  • UTMD 10-28-2025
  • Dividend Yield
  • CCCC N/A
  • UTMD 1.94%
  • EPS Growth
  • CCCC N/A
  • UTMD N/A
  • EPS
  • CCCC N/A
  • UTMD 3.74
  • Revenue
  • CCCC $34,240,000.00
  • UTMD $38,826,000.00
  • Revenue This Year
  • CCCC N/A
  • UTMD N/A
  • Revenue Next Year
  • CCCC N/A
  • UTMD N/A
  • P/E Ratio
  • CCCC N/A
  • UTMD $16.77
  • Revenue Growth
  • CCCC 16.55
  • UTMD N/A
  • 52 Week Low
  • CCCC $1.09
  • UTMD $51.26
  • 52 Week High
  • CCCC $7.14
  • UTMD $68.99
  • Technical
  • Relative Strength Index (RSI)
  • CCCC 38.70
  • UTMD 55.86
  • Support Level
  • CCCC $2.13
  • UTMD $62.22
  • Resistance Level
  • CCCC $3.43
  • UTMD $64.22
  • Average True Range (ATR)
  • CCCC 0.30
  • UTMD 1.20
  • MACD
  • CCCC -0.12
  • UTMD -0.18
  • Stochastic Oscillator
  • CCCC 6.58
  • UTMD 58.33

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

About UTMD Utah Medical Products Inc.

Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.

Share on Social Networks: